The AIDS Drug Assistance Program (ADAP) has become a critical source of prescription drugs for low-income people with HIV/AIDS who have no or limited prescription drug coverage. There are 57 ADAPs, yet nearly 30 percent do not include coverage of all FDA-approved antiretroviral (ARV) therapies on their formularies, and South Dakota does not provide any protease inhibitor (PI) coverage at all, according to the annual report of the National ADAP Monitoring Project.

Forty-two ADAPs cover enfuvirtide (Fuzeon), a recently approved fusion inhibitor. Fuzeon interferes with the entry of HIV-1 into cells by inhibiting the fusion of viral and cellular membranes. This is up from 33 ADAPs reported last year. ADAPs in Alaska, Hawaii, Idaho, Kentucky, Nebraska, New Mexico, North Dakota, South Dakota, West Virginia, and Wyoming do not extend formulary coverage to enfuvirtide.

State ADAP formulary coverage of approved antiretroviral drugs under the AIDS Drug Assistance Program

Note: 2004 data; no information for American Samoa, Guam, the Northern Mariana Islands, Marshall Islands, and the U.S. Virgin Islands.

NRTI: nucleoside reverse transcriptase inhibitor

NNRTI: non-nucleoside reverse transcriptase inhibitor

Source: National ADAP Monitoring Project. Annual Report.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.